

CITATION REPORT

List of articles citing

A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care in ambulatory COVID-19: study protocol for the ATOMIC2 trial

DOI: [10.1186/s13063-020-04593-8](https://doi.org/10.1186/s13063-020-04593-8)
Trials, 2020, 21, 718.

Source: <https://exaly.com/paper-pdf/76204659/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
20	Azithromycin in viral infections. <i>Reviews in Medical Virology</i> , 2021 , 31, e2163	11.7	36
19	COVID-19: Can early home treatment with Azithromycin alone or with Zinc help prevent hospitalisation, death, and long-COVID-19? A review.		1
18	A Journey From SARS-CoV-2 to COVID-19 and Beyond: A Comprehensive Insight of Epidemiology, Diagnosis, Pathogenesis, and Overview of the Progress into Its Therapeutic Management. <i>Frontiers in Pharmacology</i> , 2021 , 12, 576448	5.6	5
17	COVID-19 therapeutics for low- and middle-income countries: a review of re-purposed candidate agents with potential for near-term use and impact.		1
16	A randomised clinical trial of azithromycin versus standard care in ambulatory COVID-19 [The ATOMIC2 trial.		2
15	Safety and efficacy of a COVID-19 treatment with nebulized and/or intravenous neutral electrolyzed saline combined with usual medical care vs. usual medical care alone: A randomized, open-label, controlled trial. <i>Experimental and Therapeutic Medicine</i> , 2021 , 22, 915	2.1	7
14	[Potentially useful drugs in the treatment of COVID-19 in Primary Care]. <i>Semergen</i> , 2021 ,	1.9	
13	Sars-Cov-2 Infection in Patients on Long-Term Treatment with Macrolides in Spain: A National Cross-Sectional Study. <i>Antibiotics</i> , 2021 , 10,	4.9	0
12	COVID-19: potential therapeutics for pediatric patients. <i>Pharmacological Reports</i> , 2021 , 73, 1520-1538	3.9	6
11	COVID-19 Therapeutics for Low- and Middle-Income Countries: A Review of Candidate Agents with Potential for Near-Term Use and Impact. <i>American Journal of Tropical Medicine and Hygiene</i> , 2021 , 105, 584-595	3.2	3
10	Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial. <i>Lancet Respiratory Medicine</i> , 2021 , 9, 1130-1140	35.1	25
9	Azithromycin for mild-to-moderate COVID-19 - Authors'reply. <i>Lancet Respiratory Medicine</i> , 2021 , 9, e100-e101	35.1	
8	Azithromycin for mild-to-moderate COVID-19. <i>Lancet Respiratory Medicine</i> , 2021 , 9, e99	35.1	2
7	Pragmatic Recommendations for Therapeutics of Hospitalized COVID-19 Patients in Low- and Middle-Income Countries. <i>American Journal of Tropical Medicine and Hygiene</i> , 2020 ,	3.2	3
6	Antibiotics for the treatment of COVID-19. <i>The Cochrane Library</i> , 2021 , 10, CD015025	5.2	10
5	Nonantimicrobial Actions of Macrolides: Overview and Perspectives for Future Development. <i>Pharmacological Reviews</i> , 2021 , 73, 233-262	22.5	5
4	Addressing the global surge of COVID-19 cases: Insights from diagnostics, improved treatment strategies, vaccine development and application. <i>Journal of Clinical and Translational Research</i> , 2021 , 7, 127-139	1.1	1

3	SARS-CoV-2 and spp.: friend or foe? A systematic literature review.. <i>Journal of Medical Microbiology</i> , 2022 , 71,	3.2	0
2	Azithromycin through the Lens of the COVID-19 Treatment. 2022 , 11, 1063		1
1	Clinical trials and future perspectives of antiinflammatory agents. 2023 , 331-386		0